854 related articles for article (PubMed ID: 25807485)
1. Therapy-induced tumour secretomes promote resistance and tumour progression.
Obenauf AC; Zou Y; Ji AL; Vanharanta S; Shu W; Shi H; Kong X; Bosenberg MC; Wiesner T; Rosen N; Lo RS; Massagué J
Nature; 2015 Apr; 520(7547):368-72. PubMed ID: 25807485
[TBL] [Abstract][Full Text] [Related]
2. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
[TBL] [Abstract][Full Text] [Related]
3. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR; Fridlyand J; Yan Y; Penuel E; Burton L; Chan E; Peng J; Lin E; Wang Y; Sosman J; Ribas A; Li J; Moffat J; Sutherlin DP; Koeppen H; Merchant M; Neve R; Settleman J
Nature; 2012 Jul; 487(7408):505-9. PubMed ID: 22763448
[TBL] [Abstract][Full Text] [Related]
4. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
5. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
6. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
Schmitt M; Sinnberg T; Nalpas NC; Maass A; Schittek B; Macek B
Mol Cell Proteomics; 2019 Jun; 18(6):1096-1109. PubMed ID: 30890564
[TBL] [Abstract][Full Text] [Related]
9. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
10. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
12. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
14. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
15. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
16. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
18. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
19. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Porcelli L; Guida G; Quatrale AE; Cocco T; Sidella L; Maida I; Iacobazzi RM; Ferretta A; Stolfa DA; Strippoli S; Guida S; Tommasi S; Guida M; Azzariti A
J Transl Med; 2015 Jan; 13():26. PubMed ID: 25623468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
